BioWa, Inc. announced today that it is beginning its Phase 1 clinical trial to evaluate the safety and tolerability of BIW-8405, BioWa's anti-IL-5 receptor monoclonal antibody (Mab). The Mab is being developed for the treatment of asthma. [click link for full article]
(more...)